Baird analyst Brian Skorney reiterated an Outperform rating and $26.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA).The analyst commented: "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE